Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Browsing Category
DOJ
Getting Serious About Fraud – The DOJ Charges 412
With the new administration, there appears to be a renewed commitment to enforcing anti-kickback rules against healthcare…
Aegerion Resolves Criminal and Civil Actions
Aegerion recently finalized a $40.1 million settlement that resolves civil and criminal charges over its marketing of JUXTAPID®.…
AmerisourceBergen Specialty Group Pleads Guilty to Distributing Misbranded…
On September 27, 2017, AmerisourceBergen Specialty Group (ABSG), a wholly-owned subsidiary of AmerisourceBergen Corporation, one…
To Disclose or Not to Disclose… That is the Question: The DOJ’s FCPA Pilot…
It has been over one-year since the US Department of Justice has launched its pilot program aimed to incentivize companies to…
FDA Warns Cipher Over “Misleading” Marketing Materials
The United States Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) sent a warning letter to Cipher…
Celgene Settles Whistleblower Suit for $280 Million
Late July 2017, Celgene Corp., a manufacturer of pharmaceuticals, agreed to pay $280 million to settle fraud allegations related…
DOJ Announces Another FCA Settlement – Sightpath Medical and TLC…
In late August 2017, the United States Department of Justice (DOJ) announced a $12 million settlement with Sightpath Medical and…
Celgene Settles Cancer Drug Whistleblower Suit
Celgene Corporation has settled a whistleblower lawsuit for $280 million, alleging that the pharmaceutical company committed fraud…
Largest Fraud Takedown Announced by AG Sessions
On Thursday, July 13, 2017, United States Attorney General Jeff Sessions and Department of Health and Human Services (HHS)…
Effectiveness, The Holy Grail of Compliance – Both the DOJ & OIG…
Measuring the effectiveness of compliance programs is no easy task since governing agencies have not published a template that…